Prognostic value of adiponectin for cardiovascular disease and mortality.

J.M. Dekker, T. Funahashi, G. Nijpels, S. Pilz, C.D.A. Stehouwer, M.B. Snijder, L.M. Bouter, Y. Matsuzawa, I. Shimomura, R.J. Heine

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Context: Low adiponectin concentrations are associated with the presence of an adverse cardiovascular disease (CVD) risk profile. Objective: We studied the predictive value of adiponectin levels for all-cause and CVD mortality and CVD morbidity. Design, Setting, and Participants: This was a population-based cohort study in Hoorn, The Netherlands, which started in 1989 and included 2484 participants, aged 50-75 yr. Main Outcome Measures: Hazard ratios (HRs) with 95% confidence interval per SD change in log-adiponectin for all-cause and CVD mortality and CVD morbidity were calculated. Results: Adiponectin was determined for 1077 men and 1248 women. Higher adiponectin reduced the risk of nonfatal CVD in women [HR with 95% confidence interval 0.72 (0.61-0.90) in women and 0.92 (0.79-1.06) in men], but not the risk of all-cause or CVD mortality. In contrast, after adjustment for cardiovascular risk factors, higher adiponectin was a significant predictor of all-cause and CVD mortality [HR for CVD mortality 1.45 (1.10-1.92) in women and 1.30 (1.04-1.63) in men]. Higher adiponectin was associated with an increased risk of CVD mortality in people with prevalent CVD [HR 1.27 (0.98-1.63)] and with reduced risk in people without [HR 0.90 (0.73-1.11)]. After adjustment for cardiovascular risk factors, the HRs for CVD mortality were 1.60 (1.14-2.23) for patients with and 1.38 (1.06-1.80) for patients without prevalent CVD. Conclusions: High levels of adiponectin predict mortality, in particular in patients with prevalent CVD. We hypothesize that adiponectin protects against metabolic and vascular diseases, but in patients already afflicted with CVD, adiponectin is compensatory up-regulated and, therefore, indicates a high mortality risk. Copyright © 2008 by The Endocrine Society.
Original languageEnglish
Pages (from-to)1489-1496
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume93
DOIs
Publication statusPublished - 2008

Fingerprint

Adiponectin
Cardiovascular Diseases
Mortality
Hazards
Confidence Intervals
Morbidity
Metabolic Diseases
Vascular Diseases
Netherlands

Cite this

Dekker, J. M., Funahashi, T., Nijpels, G., Pilz, S., Stehouwer, C. D. A., Snijder, M. B., ... Heine, R. J. (2008). Prognostic value of adiponectin for cardiovascular disease and mortality. Journal of Clinical Endocrinology and Metabolism, 93, 1489-1496. https://doi.org/10.1210/jc.2007-1436
Dekker, J.M. ; Funahashi, T. ; Nijpels, G. ; Pilz, S. ; Stehouwer, C.D.A. ; Snijder, M.B. ; Bouter, L.M. ; Matsuzawa, Y. ; Shimomura, I. ; Heine, R.J. / Prognostic value of adiponectin for cardiovascular disease and mortality. In: Journal of Clinical Endocrinology and Metabolism. 2008 ; Vol. 93. pp. 1489-1496.
@article{5087c39fefac4f1495b3d1388601151c,
title = "Prognostic value of adiponectin for cardiovascular disease and mortality.",
abstract = "Context: Low adiponectin concentrations are associated with the presence of an adverse cardiovascular disease (CVD) risk profile. Objective: We studied the predictive value of adiponectin levels for all-cause and CVD mortality and CVD morbidity. Design, Setting, and Participants: This was a population-based cohort study in Hoorn, The Netherlands, which started in 1989 and included 2484 participants, aged 50-75 yr. Main Outcome Measures: Hazard ratios (HRs) with 95{\%} confidence interval per SD change in log-adiponectin for all-cause and CVD mortality and CVD morbidity were calculated. Results: Adiponectin was determined for 1077 men and 1248 women. Higher adiponectin reduced the risk of nonfatal CVD in women [HR with 95{\%} confidence interval 0.72 (0.61-0.90) in women and 0.92 (0.79-1.06) in men], but not the risk of all-cause or CVD mortality. In contrast, after adjustment for cardiovascular risk factors, higher adiponectin was a significant predictor of all-cause and CVD mortality [HR for CVD mortality 1.45 (1.10-1.92) in women and 1.30 (1.04-1.63) in men]. Higher adiponectin was associated with an increased risk of CVD mortality in people with prevalent CVD [HR 1.27 (0.98-1.63)] and with reduced risk in people without [HR 0.90 (0.73-1.11)]. After adjustment for cardiovascular risk factors, the HRs for CVD mortality were 1.60 (1.14-2.23) for patients with and 1.38 (1.06-1.80) for patients without prevalent CVD. Conclusions: High levels of adiponectin predict mortality, in particular in patients with prevalent CVD. We hypothesize that adiponectin protects against metabolic and vascular diseases, but in patients already afflicted with CVD, adiponectin is compensatory up-regulated and, therefore, indicates a high mortality risk. Copyright {\circledC} 2008 by The Endocrine Society.",
author = "J.M. Dekker and T. Funahashi and G. Nijpels and S. Pilz and C.D.A. Stehouwer and M.B. Snijder and L.M. Bouter and Y. Matsuzawa and I. Shimomura and R.J. Heine",
year = "2008",
doi = "10.1210/jc.2007-1436",
language = "English",
volume = "93",
pages = "1489--1496",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "Oxford University Press",

}

Dekker, JM, Funahashi, T, Nijpels, G, Pilz, S, Stehouwer, CDA, Snijder, MB, Bouter, LM, Matsuzawa, Y, Shimomura, I & Heine, RJ 2008, 'Prognostic value of adiponectin for cardiovascular disease and mortality.' Journal of Clinical Endocrinology and Metabolism, vol. 93, pp. 1489-1496. https://doi.org/10.1210/jc.2007-1436

Prognostic value of adiponectin for cardiovascular disease and mortality. / Dekker, J.M.; Funahashi, T.; Nijpels, G.; Pilz, S.; Stehouwer, C.D.A.; Snijder, M.B.; Bouter, L.M.; Matsuzawa, Y.; Shimomura, I.; Heine, R.J.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 93, 2008, p. 1489-1496.

Research output: Contribution to JournalArticleAcademicpeer-review

TY - JOUR

T1 - Prognostic value of adiponectin for cardiovascular disease and mortality.

AU - Dekker, J.M.

AU - Funahashi, T.

AU - Nijpels, G.

AU - Pilz, S.

AU - Stehouwer, C.D.A.

AU - Snijder, M.B.

AU - Bouter, L.M.

AU - Matsuzawa, Y.

AU - Shimomura, I.

AU - Heine, R.J.

PY - 2008

Y1 - 2008

N2 - Context: Low adiponectin concentrations are associated with the presence of an adverse cardiovascular disease (CVD) risk profile. Objective: We studied the predictive value of adiponectin levels for all-cause and CVD mortality and CVD morbidity. Design, Setting, and Participants: This was a population-based cohort study in Hoorn, The Netherlands, which started in 1989 and included 2484 participants, aged 50-75 yr. Main Outcome Measures: Hazard ratios (HRs) with 95% confidence interval per SD change in log-adiponectin for all-cause and CVD mortality and CVD morbidity were calculated. Results: Adiponectin was determined for 1077 men and 1248 women. Higher adiponectin reduced the risk of nonfatal CVD in women [HR with 95% confidence interval 0.72 (0.61-0.90) in women and 0.92 (0.79-1.06) in men], but not the risk of all-cause or CVD mortality. In contrast, after adjustment for cardiovascular risk factors, higher adiponectin was a significant predictor of all-cause and CVD mortality [HR for CVD mortality 1.45 (1.10-1.92) in women and 1.30 (1.04-1.63) in men]. Higher adiponectin was associated with an increased risk of CVD mortality in people with prevalent CVD [HR 1.27 (0.98-1.63)] and with reduced risk in people without [HR 0.90 (0.73-1.11)]. After adjustment for cardiovascular risk factors, the HRs for CVD mortality were 1.60 (1.14-2.23) for patients with and 1.38 (1.06-1.80) for patients without prevalent CVD. Conclusions: High levels of adiponectin predict mortality, in particular in patients with prevalent CVD. We hypothesize that adiponectin protects against metabolic and vascular diseases, but in patients already afflicted with CVD, adiponectin is compensatory up-regulated and, therefore, indicates a high mortality risk. Copyright © 2008 by The Endocrine Society.

AB - Context: Low adiponectin concentrations are associated with the presence of an adverse cardiovascular disease (CVD) risk profile. Objective: We studied the predictive value of adiponectin levels for all-cause and CVD mortality and CVD morbidity. Design, Setting, and Participants: This was a population-based cohort study in Hoorn, The Netherlands, which started in 1989 and included 2484 participants, aged 50-75 yr. Main Outcome Measures: Hazard ratios (HRs) with 95% confidence interval per SD change in log-adiponectin for all-cause and CVD mortality and CVD morbidity were calculated. Results: Adiponectin was determined for 1077 men and 1248 women. Higher adiponectin reduced the risk of nonfatal CVD in women [HR with 95% confidence interval 0.72 (0.61-0.90) in women and 0.92 (0.79-1.06) in men], but not the risk of all-cause or CVD mortality. In contrast, after adjustment for cardiovascular risk factors, higher adiponectin was a significant predictor of all-cause and CVD mortality [HR for CVD mortality 1.45 (1.10-1.92) in women and 1.30 (1.04-1.63) in men]. Higher adiponectin was associated with an increased risk of CVD mortality in people with prevalent CVD [HR 1.27 (0.98-1.63)] and with reduced risk in people without [HR 0.90 (0.73-1.11)]. After adjustment for cardiovascular risk factors, the HRs for CVD mortality were 1.60 (1.14-2.23) for patients with and 1.38 (1.06-1.80) for patients without prevalent CVD. Conclusions: High levels of adiponectin predict mortality, in particular in patients with prevalent CVD. We hypothesize that adiponectin protects against metabolic and vascular diseases, but in patients already afflicted with CVD, adiponectin is compensatory up-regulated and, therefore, indicates a high mortality risk. Copyright © 2008 by The Endocrine Society.

U2 - 10.1210/jc.2007-1436

DO - 10.1210/jc.2007-1436

M3 - Article

VL - 93

SP - 1489

EP - 1496

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

ER -